The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.
Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique …
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis.
[This corrects the article DOI: 10.3389/fimmu.2021.641206.].
Case Report: Diagnostic challenges in cervical small cell neuroendocrine carcinoma of a reproductive-age woman.
Small cell neuroendocrine carcinoma of the cervix (SCNEC) is a rare and highly aggressive malignancy with a poor prognosis. We report the case of a 36-year-old nulliparous woman with a …
Nanodrug impact on female reproductive health and fetal development: From translation approaches to long-term safety concern.
Biomaterials for drug delivery offer significant advantages over conventional medications, including enhanced cellular uptake, improved drug stability, targeted delivery, and controlled drug release. Cutting-edge nanodrugs delivery approaches such as drugs …
Macrophages in endometriosis: key roles and emerging therapeutic opportunities-a narrative review.
Endometriosis is a chronic gynecological disorder affecting approximately 10% of women of reproductive age. It commonly presents with pelvic pain, dysmenorrhea, and infertility, imposing substantial physical, psychological, and social burdens. …
Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials - BMC Cancer
Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials BMC Cancer